This HTML5 document contains 136 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00492/identifier/kegg-compound/
n10http://linked.opendata.cz/resource/AHFS/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00492/identifier/pubchem-compound/
foafhttp://xmlns.com/foaf/0.1/
n31http://linked.opendata.cz/resource/mesh/concept/
n18http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/mixture/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00492/identifier/pubchem-substance/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00492/identifier/kegg-drug/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00492/identifier/drugbank/
n28http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00492/identifier/national-drug-code-directory/
n26http://www.pdrhealth.com/drugs/rx/
admshttp://www.w3.org/ns/adms#
n29http://www.rxlist.com/cgi/generic/
n23http://linked.opendata.cz/resource/drugbank/patent/
n32http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00492/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n30http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n25http://www.drugs.com/cdi/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00492/identifier/chebi/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n33http://linked.opendata.cz/resource/drugbank/drug/DB00492/identifier/wikipedia/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00492/identifier/pharmgkb/
n22http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00492
rdf:type
n3:Drug
n3:description
Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
n3:dosage
n21:271B5DD3-363D-11E5-9242-09173F13E4C5 n21:271B5DD4-363D-11E5-9242-09173F13E4C5 n21:271B5DD5-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# David D, Jallad N, Germino FW, Willett MS, de Silva J, Weidner SM, Mills DJ: A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough. Am J Ther. 1995 Oct;2(10):806-813. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11854791 # Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11329095
n3:group
approved
n3:halfLife
12 hours
n3:indication
For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
n3:manufacturer
n18:271B5DBB-363D-11E5-9242-09173F13E4C5 n18:271B5DB5-363D-11E5-9242-09173F13E4C5 n18:271B5DB6-363D-11E5-9242-09173F13E4C5 n18:271B5DB4-363D-11E5-9242-09173F13E4C5 n18:271B5DB9-363D-11E5-9242-09173F13E4C5 n18:271B5DBA-363D-11E5-9242-09173F13E4C5 n18:271B5DB7-363D-11E5-9242-09173F13E4C5 n18:271B5DB8-363D-11E5-9242-09173F13E4C5
owl:sameAs
n28:DB00492 n32:DB00492
dcterms:title
Fosinopril
adms:identifier
n7:PA449710 n8:55891 n11:D00622 n12:62037-935-90 n13:46506495 n14:5163 n15:C07016 n16:50469 n17:DB00492 n33:Fosinopril
n3:mechanismOfAction
There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Fosinoprilat, the active metabolite of fosinopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Fosinoprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
n3:packager
n18:271B5D99-363D-11E5-9242-09173F13E4C5 n18:271B5D9A-363D-11E5-9242-09173F13E4C5 n18:271B5DA1-363D-11E5-9242-09173F13E4C5 n18:271B5DA2-363D-11E5-9242-09173F13E4C5 n18:271B5D9F-363D-11E5-9242-09173F13E4C5 n18:271B5DA0-363D-11E5-9242-09173F13E4C5 n18:271B5D9D-363D-11E5-9242-09173F13E4C5 n18:271B5D9E-363D-11E5-9242-09173F13E4C5 n18:271B5D9B-363D-11E5-9242-09173F13E4C5 n18:271B5D9C-363D-11E5-9242-09173F13E4C5 n18:271B5DA9-363D-11E5-9242-09173F13E4C5 n18:271B5DAA-363D-11E5-9242-09173F13E4C5 n18:271B5DA7-363D-11E5-9242-09173F13E4C5 n18:271B5DA8-363D-11E5-9242-09173F13E4C5 n18:271B5DA5-363D-11E5-9242-09173F13E4C5 n18:271B5DA6-363D-11E5-9242-09173F13E4C5 n18:271B5DA3-363D-11E5-9242-09173F13E4C5 n18:271B5DA4-363D-11E5-9242-09173F13E4C5 n18:271B5DB1-363D-11E5-9242-09173F13E4C5 n18:271B5DB2-363D-11E5-9242-09173F13E4C5 n18:271B5DAF-363D-11E5-9242-09173F13E4C5 n18:271B5DB0-363D-11E5-9242-09173F13E4C5 n18:271B5DAD-363D-11E5-9242-09173F13E4C5 n18:271B5DAE-363D-11E5-9242-09173F13E4C5 n18:271B5DAB-363D-11E5-9242-09173F13E4C5 n18:271B5DAC-363D-11E5-9242-09173F13E4C5 n18:271B5DB3-363D-11E5-9242-09173F13E4C5
n3:patent
n23:5006344
n3:routeOfElimination
After oral administration of radiolabeled fosinopril, approximately half of the absorbed dose is excreted in the urine and the remainder is excreted in the feces.
n3:synonym
(2S,4S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid (S)-4-Cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid (2S,4S)-4-Cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Fosinopril
n3:toxicity
Human overdoses of fosinopril have not been reported, but the most common manifestation of human fosinopril overdosage is likely to be hypotension. Oral doses of fosinopril at 2600 mg/kg in rats were associated with significant lethality. The most common adverse effects include dizzines, cough, fatigue, and headache.
n9:hasAHFSCode
n10:24-32-04
n3:foodInteraction
High salt intake may attenuate the antihypertensive effect of fosinopril. Herbs that may attenuate the antihypertensive effect of fosinopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice. Do not take calcium, aluminum, magnesium or iron supplements, or antacids within 2 hours of taking this medication. Take without regard to meals. Fosinopril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
n3:mixture
n19:271B5D98-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Fosinoprilat is ≥95% protein bound
n3:salt
n3:synthesisReference
Sandra Gallego Pato, Antonio Palomo Coll, Francisco Palomo Nicolau, "Preparation of crystalline polymorphs of fosinopril sodium." U.S. Patent US20050010054, issued January 13, 2005.
n30:hasConcept
n31:M0026315
foaf:page
n25:fosinopril.html n26:rx-mono.aspx?contentFileName=Mon1274.html&contentName=Monopril&contentId= n29:fosinop.htm
n3:IUPAC-Name
n5:271B5DDA-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B5DE0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B5DDF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B5DDC-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B5DDD-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B5DDE-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B5DF0-363D-11E5-9242-09173F13E4C5 n5:271B5DD8-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B5DD9-363D-11E5-9242-09173F13E4C5 n5:271B5DD6-363D-11E5-9242-09173F13E4C5 n5:271B5DF2-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B5DD7-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n22:C09AA09
n3:H-Bond-Acceptor-Count
n5:271B5DE6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B5DE7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B5DE1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B5DE2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B5DE4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B5DE3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B5DE5-363D-11E5-9242-09173F13E4C5
n3:absorption
Average absolute absorption is 36%. The primary site of absorption is the proximal small intestine (duodenum/jejunum). Food slows the rate of absorption with no effect on the extent of absorption.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
98048-97-6
n3:clearance
* 26 - 39 mL/min [healthy]
n3:containedIn
n4:271B5DBE-363D-11E5-9242-09173F13E4C5 n4:271B5DBF-363D-11E5-9242-09173F13E4C5 n4:271B5DBC-363D-11E5-9242-09173F13E4C5 n4:271B5DBD-363D-11E5-9242-09173F13E4C5 n4:271B5DD2-363D-11E5-9242-09173F13E4C5 n4:271B5DD0-363D-11E5-9242-09173F13E4C5 n4:271B5DD1-363D-11E5-9242-09173F13E4C5 n4:271B5DCE-363D-11E5-9242-09173F13E4C5 n4:271B5DCF-363D-11E5-9242-09173F13E4C5 n4:271B5DC4-363D-11E5-9242-09173F13E4C5 n4:271B5DCD-363D-11E5-9242-09173F13E4C5 n4:271B5DC5-363D-11E5-9242-09173F13E4C5 n4:271B5DC6-363D-11E5-9242-09173F13E4C5 n4:271B5DCB-363D-11E5-9242-09173F13E4C5 n4:271B5DCC-363D-11E5-9242-09173F13E4C5 n4:271B5DC9-363D-11E5-9242-09173F13E4C5 n4:271B5DCA-363D-11E5-9242-09173F13E4C5 n4:271B5DC7-363D-11E5-9242-09173F13E4C5 n4:271B5DC8-363D-11E5-9242-09173F13E4C5 n4:271B5DC2-363D-11E5-9242-09173F13E4C5 n4:271B5DC3-363D-11E5-9242-09173F13E4C5 n4:271B5DC0-363D-11E5-9242-09173F13E4C5 n4:271B5DC1-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B5DEC-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B5DEE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B5DEF-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B5DF1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B5DEB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B5DEA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B5DED-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B5DDB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B5DE8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B5DE9-363D-11E5-9242-09173F13E4C5